Stock DVAX DYNAVAX TECHNOLOGIES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Company Dynavax Technologies Corporation

Equities

DVAX

US2681582019

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
11.21 USD +0.36% Intraday chart for Dynavax Technologies Corporation -5.00% -19.81%
04-01 Dynavax Technologies Corporation Announces Chief Financial Officer Changes CI
02-23 Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue MT

Business Summary

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Number of employees: 408

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Vaccines
100.0 %
723 100.0 % 232 100.0 % -67.86%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
99.4 %
134 18.5 % 231 99.4 % +72.64%
Non-United States
0.6 %
589 81.5 % 1 0.6 % -99.77%

Managers

Managers TitleAgeSince
Ryan Spencer CEO
 Chief Executive Officer 46 31/12/04
David Novack PSD
 President 62 24/03/13
Patricia Novy CTO
 Chief Tech/Sci/R&D Officer - 31/12/20
Todd Lopeman CTO
 Chief Tech/Sci/R&D Officer - 31/12/13
Robert Janssen CTO
 Chief Tech/Sci/R&D Officer 70 31/12/09
Nicole Arndt IRC
 Investor Relations Contact - -
Alex Oh PRN
 Corporate Officer/Principal - 31/12/21
Riccardo Manetti PRN
 Corporate Officer/Principal - 31/12/19
Meg Smith PRN
 Corporate Officer/Principal - 31/12/18
Dong Yu PRN
 Corporate Officer/Principal - 07/02/21

Members of the board

Members of the board TitleAgeSince
Francis Cano BRD
 Director/Board Member 79 02/11/09
Peggy Phillips BRD
 Director/Board Member 70 31/07/06
Dan Kisner BRD
 Director/Board Member 77 21/07/10
Julia Eastland BRD
 Director/Board Member 59 16/07/20
Elaine Sun BRD
 Director/Board Member 53 09/12/21
Scott Myers CHM
 Chairman 57 18/10/21
Ryan Spencer CEO
 Chief Executive Officer 46 31/12/04
Brent MacGregor BRD
 Director/Board Member 60 16/07/20
Peter Paradiso BRD
 Director/Board Member 73 22/09/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 130,862,916 130,455,328 ( 99.69 %) 0 99.69 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
16.99 %
22,185,582 16.99 % 275 M $
Federated Global Investment Management Corp.
8.701 %
11,364,666 8.701 % 141 M $
STATE STREET CORPORATION
7.270 %
9,495,785 7.270 % 118 M $
Vanguard Fiduciary Trust Co.
7.102 %
9,275,788 7.102 % 115 M $
Deep Track Capital LP
5.431 %
7,093,214 5.431 % 88 M $
Chicago Capital LLC
4.320 %
5,642,409 4.320 % 70 M $
Dimensional Fund Advisors LP
3.087 %
4,032,139 3.087 % 50 M $
Goldman Sachs Asset Management LP
2.754 %
3,597,139 2.754 % 45 M $
Eventide Asset Management LLC
2.215 %
2,893,435 2.215 % 36 M $
Geode Capital Management LLC
2.160 %
2,820,898 2.160 % 35 M $
NameEquities%Valuation
Bain Capital Life Sciences LP
4.354 %
1,891 4.354 % 23 467 $

Company contact information

Dynavax Technologies Corp.

2100 Powell Street Suite 900

94608, Emeryville

+510 848 5100

http://www.dynavax.com
address Dynavax Technologies Corporation(DVAX)

Group companies

NameCategory and Sector
Dynavax India LLP

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Dynavax Technologies Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.21 USD
Average target price
24.67 USD
Spread / Average Target
+120.04%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
DYNAVAX TECHNOLOGIES CORPORATION Stock Dynavax Technologies Corporation
-19.81% 1.47B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. DVAX Stock
  4. Company Dynavax Technologies Corporation